Neurology Central

Aimovig® receives positive CHMP opinion for the prevention of migraine

Novartis (Frimley, UK) have announced that they have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the use of Aimovig® (erenumab) for the prevention of migraine in adult patients who experience more than 4 migraine days per month.

If Aimovig is approved, then it will be the first and only preventive treatment designed specifically to block the calcitonin gene-related peptide (CGRP) receptor which is thought to be responsible for transmitting pain signals associated with migraine. 

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.